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Cancer develops not only as a result of genetic mutations
and genomic rearrangements, but also as a consequence
of numerous epigenetic alterations, including extensive
changes in the distribution of DNA methylation through-
out the genome. DNA methylation changes contribute
directly to cancer by transcriptional silencing of tumor-
suppressor genes through promoter CpG island hyper-
methylation. Broad epigenomic analysis of human tumors
can reveal relationships between large numbers of epige-
netic events and can provide insight into the mechanisms
underlying concerted epigenetic change. Genomic loci tar-
geted by Polycomb Group Repressors in embryonic stem
cells, and involved in cellular differentiation, are predis-
posed to aberrant DNA methylation in cancer cells, sug-
gesting that an epigenetic block to cellular differentiation
may sometimes be an initiating event in carcinogenesis.
The very strong associations between distinct epigenetic
subtypes, such as CpG Island Methylator Phenotypes
(CIMP) and specific somatic genetic events, such as BRAF
mutation in colorectal cancer and IDH1 mutation in glio-
blastoma multiforme are consistent with an early role for
DNA methylation alterations, providing a favorable cellu-
lar context for the subsequent somatic mutation. The ana-
lysis of whole methylomes at single-basepair resolution
reveals that cancer-associated changes occur differentially
across defined regions of the genome associated with the
nuclear lamina. It is apparent that epigenomic analysis is
essential for a full understanding of the relationship
between alterations in the cancer genome and the origin
and clinical diversity of individual tumors.
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